Published in Clinical Oncology Week, April 10th, 2006
"There is growing clinical interest in thalidomide for the treatment of various disorders due to its anti-inflammatory, immunomodulatory, and antiangiogenic properties. In numerous clinical trials thalidomide is used as an adjunct to standard therapy," scientists in Switzerland report.
"Therefore, clinicians should be aware of all possible drug-drug interactions that might occur with this drug. P-gp, a drug efflux transporter that is expressed in many tissues, is the cause of several drug-drug interactions. P-gp induction or inhibition can lead to ineffective therapy or side-effects,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.